

REPORT DOCUMENTATION PAGE					Form Approved OMB No. 0704-0188	
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.						
1. REPORT DATE (DD-MM-YYYY) 12-02-2013		2. REPORT TYPE Final		3. DATES COVERED (From - To) Nov 2010-Jul 2013		
4. TITLE AND SUBTITLE Intramuscular cobinamide versus intravenous hydroxocobalamin in the treatment of acute, severe cyanide induced cardiotoxicity of severe hypotension and of cardiac arrest in a swine (Sus Scrofa) model Intravenous cobinamide, a novel cyanide antidote, versus hydroxocobalamin in the treatment of acute cyanide toxicity and apnea in a swine (Sus Scrofa) model				5a. CONTRACT NUMBER		
				5b. GRANT NUMBER FWH20100170A		
				5c. PROGRAM ELEMENT NUMBER		
				5d. PROJECT NUMBER FWH20100170A		
6. AUTHOR(S) Bebarta, Vikhyat S. Boss, Gerry Boudreau, Susan M. Castaneda, Maria G. Tanen, David				5e. TASK NUMBER		
				5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Medical Operations Squadron Wilford Hall Ambulatory Surgical Center 2200 Bergquist Drive Bldg 4550 Lackland AFB, TX 78236				8. PERFORMING ORGANIZATION REPORT NUMBER FWH20100170A		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of the Air Force Surgeon General Directorate for Modernization, SGRS 5201 Leesburg Pike, Suite 1206 Falls Church, VA 22401				10. SPONSOR/MONITOR'S ACRONYM(S)		
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/AVAILABILITY STATEMENT Distribution A. Approved for public release; distribution unlimited.						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Obj: Compare time to breathing between 3 groups of swine (11/group) with cyanide(CN) induced apnea; treated with intravenous(IV) hydroxocobalamin(HOC), IV cobinamide(COB), or IV normal saline(NS) control. Method:33 swine(45-55kg) intubated, anesthetized & instrumented (MAP and cardiac output). Isoflurane low to allow breathing; room air(0.21FiO2). CN infused until apnea. Given HOC(65mg/kg), COB(12.5mg/kg) or NS(20ml) & monitored 60min. Results:Weight, time to apnea, & CN dose similar (p>0.10). At treatment, blood CN, lactate levels, & decrease in MAP similar (p>0.10). 2/11 swine in NS group survived(p<0.001), compared to 10/11 in HOC & 10/11 in COB group. Time to breaths post treatment similar(HOC 1:48min, COB 1:49min). Blood CN levels undetectable post HOC or COB infusion. No statistically significant differences were detected between groups for CO, MAP, RR, or min vent at 60min. Lactate, pH, and PCO2 at 60 min were similar (p>0.10). Conclusion: IV COB led to similar time to breathing as IV HOC for CN induced apnea and severe toxicity. Cobinamide was 5 times as potent as hydroxocobalamin.						
15. SUBJECT TERMS hydroxocobalamin, cobinamide, cyanide, poisoning, Vitamin B12a, Vit B12, hypotension, cardiac arrest, apnea						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON	
a. REPORT	b. ABSTRACT	c. THIS PAGE			Vikhyat S. Bebarta, MD	
U	U	U	SAR		19b. TELEPHONE NUMBER (Include area code) 210-275-3794	

Title: Intravenous cobinamide, a novel cyanide antidote, versus hydroxocobalamin in the treatment of acute cyanide toxicity and apnea in a swine (*Sus Scrofa*) model

Background: Hydroxocobalamin (HOC) is an FDA approved antidote for cyanide (CN) toxicity.

Cobinamide (COB) is a novel antidote that has two cyanide binding sites, is more potent than HOC, and can be infused in a small volume, but its efficacy has not been clearly established. No study has directly compared HOC to COB in a severe, cyanide-toxic large animal model.

Objective: To compare the time to spontaneous breathing between 3 groups of swine with acute CN induced apnea and treated with IV HOC, IV COB, or IV normal saline (NS) control.

Methods: 33 swine (45-55 kg) intubated, anesthetized and instrumented (continuous MAP and cardiac output (CO)). Inhaled anesthesia lowered to allow spontaneous breath on room air (0.21 FiO₂). CN infused until apnea. Observed 1min before treatment. 11 swine per group randomly assigned to IV HOC (65mg/kg), IV COB (12.5mg/kg) or NS (20ml) and monitored for 60min. **Results:** Baseline weight, time to apnea, and CN dose were similar ($p>0.10$). At treatment, blood CN, lactate levels, and decrease in MAP from baseline were similar ($p>0.10$). 2/11 animals in NS group survived ($p<0.001$), compared to 10/11 in HOC group and 10/11 in COB group. Time to spontaneous breaths post antidote was similar (HOC 1:48 min:sec, COB 1:49 min:sec). Blood CN levels undetectable post HOC or COB infusion. No statistically significant differences were detected between groups for CO, MAP, RR, or min ventilation at 60 min. Lactate, pH, and PCO₂ at 60 min were similar ($p>0.10$). **Conclusion:** Intravenous cobinamide led to a similar time to spontaneous respirations as intravenous hydroxocobalamin for cyanide induced apnea and severe toxicity. Cobinamide was 5 times as potent as hydroxocobalamin.